NEOGENOMICS, INC. (NASDAQ:NEO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

6

NEOGENOMICS, INC. (NASDAQ:NEO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02.

Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

Effective April 18, 2017, Mark Machulcz, Vice President of
Operations has left NeoGenomics, Inc. (the Company) to pursue
other opportunities.On an interim basis, our California
operations will report to Robert Shovlin, the President of our
Clinical Services division while our Florida, Tennessee and Texas
operations will report to Dr. Steven Brodie, who has been
appointed Vice President of Operations.

Item 8.01.

Other Events.

On April 19, 2017, Edwin F. Weidig III, was promoted to Vice
President of Finance and he will also continue to serve as the
Principal Accounting Officer for NeoGenomics Inc.Mr. Weidig has
served as our Corporate Controller since October 2007 and as our
Director of Finance and Principal Accounting Officer since
January 2012.

Item 9.01.

Financial Statements and Exhibits.

(a)

Not applicable

(b)

Not applicable

(c)

Not applicable

(d)

Not applicable


About NEOGENOMICS, INC. (NASDAQ:NEO)

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.

NEOGENOMICS, INC. (NASDAQ:NEO) Recent Trading Information

NEOGENOMICS, INC. (NASDAQ:NEO) closed its last trading session down -0.09 at 8.53 with 369,196 shares trading hands.

An ad to help with our costs